Glutamatergic, noradrenergic, serotonergic, and cholinergic systems play a critical role in the basal ganglia circuitry. Targeting these non-dopaminergic receptors remains a focus of ongoing research to improve Parkinson's disease (PD) motor symptoms, without the potential side effects of dopamine replacement therapy. This review updates advancements in non-dopaminergic treatments for motor control in PD since 2013. To date, no non-dopaminergic selective drug has shown significant long-term efficacy as monotherapy in PD. The largest area of development in non-dopaminergic targets has been for motor complications of dopamine replacement therapy (motor fluctuations and dyskinesia). For treatment of motor fluctuations, safinamide, zonisamide, and istradefylline are currently approved, and novel glutamatergic and serotonergic drugs are in development. Long-acting formulations of amantadine are approved for treating dyskinesia. Several non-dopaminergic drugs have failed to show anti-dyskinetic efficacy, while some are still in development. Non-dopaminergic targets are also being pursued to treat specific motor symptoms of PD. For example, CX-8998 (a calcium channel modulator) is being evaluated for PD tremor and rivastigmine may improve gait dysfunction in PD. Drug repurposing continues to be a key strategy for non-dopaminergic targets in PD, but the field needs to increase discovery and availability of such drugs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s40263-020-00754-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Clinically Oriented Review of New Antipsychotics for Schizophrenia.
Neuropsychiatr Dis Treat
December 2024
Department of Medicine and Surgery, Kore University of Enna, Enna (EN), Italy.
Article Synopsis
- Current antipsychotics mainly target dopamine but often fail to address the complexity of schizophrenia and can cause significant side effects, highlighting a need for new treatments.
- Recent research is focusing on non-dopaminergic antipsychotics, such as muscarinic agonists and 5-HT2A antagonists, to offer better therapeutic options for schizophrenia.
- While new drugs like xanomeline-trospium have been approved, others like bitopertin and pimavanserin were halted in development, emphasizing the need for cautious evaluation of their efficacy and safety.
Corticostriatal glutamate-mediated dynamic therapeutic efficacy of electroacupuncture in a parkinsonian rat model.
Clin Transl Med
December 2024
Department of Physiology and Pathophysiology, School of Basic Medical Science, Capital Medical University, Beijing, China.
Background: Motor impairments are the defining cardinal features of Parkinson's disease (PD), resulting from malfunction of the cortico-basal ganglia circuit. Clinical data have demonstrated that electroacupuncture (EA) stimulation may benefit motor symptoms in PD without adverse effects. However, the specific effects of EA on PD and the underlying mechanisms remain largely unclear.
View Article and Find Full Text PDFNovel perspective of therapeutic modules to overcome motor and nonmotor symptoms in Parkinson's disease.
AIMS Neurosci
September 2024
Institute of Pharmaceutical Sciences, University of Lucknow, India.
Parkinson's disease (PD) is a neurodegenerative disorder that involves the loss of dopaminergic neurons, which leads to motor and non-motor symptoms that have a significant impact. The pathophysiology of PD is complex and involves environmental and genetic factors that contribute to alpha-synuclein aggregation, mitochondrial dysfunction, oxidative stress, and neuroinflammation. The current treatments of PD primarily focus on symptom management and have limitations in addressing disease progression and non-motor symptoms.
View Article and Find Full Text PDFBBPT attenuated 6-OHDA-induced toxicity by modulating oxidative stress, apoptotic, and inflammatory proteins in primary neurons and rat models of Parkinson's disease.
Neurotoxicology
December 2024
Neuropharmaceutical Chemistry Laboratory, Dr. B. R. Ambedkar Centre for Biomedical Research, North Campus, University of Delhi, Delhi 110007, India. Electronic address:
Parkinson's disease (PD) results from the degeneration of dopaminergic neurons in substantia nigra pars compacta (SNpc). Adenosine AR acting through the striato-pallidal pathway has emerged as a non-dopaminergic target in the therapy of PD. In the present work, the anti-parkinsonian potential of (4E)-4-(4-bromobenzylideneamino)-3-phenyl-2,3-dihydro-2-thioxo- thiazole-5-carbonitrile (BBPT) was explored.
View Article and Find Full Text PDFPositron Emission Tomography Imaging of Synaptic Dysfunction in Parkinson's Disease.
Neurosci Bull
June 2024
Department of Nuclear Medicine and PET Center, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, 310009, China.
Article Synopsis
- Parkinson's disease (PD) is a common neurodegenerative condition characterized by the buildup of alpha-synuclein, which disrupts dopamine and other neurotransmitter systems.
- The main pathology of PD involves the loss of dopamine-producing neurons, leading to significant changes in brain function.
- This review highlights how PET imaging can help visualize and understand synaptic dysfunction in PD, covering key targets, imaging agents, and the potential benefits for patient care.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!